跳至主要内容
临床试验/ACTRN12622001030763
ACTRN12622001030763尚未招募未知

A prospective, open-label, single center, single arm study of 99mTc- Hynic PSMA (TLX 599) SPECT/CT in disease staging and response monitoring in patients with progressive PSMA-positive metastatic prostate cancer

Fiona Stanley Hospital0 个研究点目标入组 20 人开始时间: 2022年7月22日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1.Male patients aged> 18 yrs
  • 2.History of histologically confirmed prostate cancer
  • 3.Metastatic patients who are considered for treatment with 177 Lu – PSMA
  • 4.Ability to understand and the willingness to sign a written informed consent

排除标准

  • 1.Life expectancy less than 6 months;
  • 2.Unable to give informed consent
  • 3.Unable to comply with required scanning schedule.
  • 4.Other malignant tumors that are likely to express PSMA, such as salivary gland, renal or hepatocellular carcinoma.

研究者

相似试验